Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

NCT00573378 | Terminated Phase 2 Results DMC FDA Drug

• 2 other identifiers: UMCC 2006.128HUM9600
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) who have achieved a complete cytogenetic response (CCyR) on imatinib (IM) or nilotinib (N) can then be treated with a combination of the tyrosine kinase inhibitor (TKI) and interferon-α2b (PEG-IFN-a2b, \[IFN\]) for 2 years, subsequently have their therapy discontinued, and then maintain a durable molecular response off all therapy. Relapse-free survival (RFS) rate 1 year after discontinuation of the TKI and IFN will be the measurement of this objective.

Conditions

Chronic Myeloid Leukemia

Keywords

CML

Outcome Measures

Primary Outcomes (1)

• Relapse-free Survival (RFS) Rate 1 Year After Discontinuation of the TKI and IFN

  To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) who have achieved a complete cytogenetic response (CCyR) on imatinib (IM) or nilotinib (N) can then be treated with a combination of the tyrosine kinase inhibitor (TKI) and interferon-α2b (PEG-IFN-a2b, \[IFN\]) for 2 years, subsequently have their therapy discontinued, and then maintain a durable molecular response off all therapy. Relapse-free survival (RFS) rate 1 year after discontinuation of the TKI and IFN will be the measurement of this objective.

  3 years (2 years of treatment with TKI and IFN + 1 year of follow-up)

Secondary Outcomes (1)

• Quantitative Reverse Transcriptase-polymerase Chain Reaction (qRT-PCR) for the Bcr-Abl Transcript.

  3 years (2 years of treatment with TKI and IFN + 1 year of follow-up)

Study Arms (1)

PEG-IFN-a2b

EXPERIMENTAL

Drug: PEG-IFN-a2b

Interventions

PEG-IFN-a2b DRUG

Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.

Also known as: Pegintron®

PEG-IFN-a2b

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have a diagnosis of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia in chronic phase by having met all of the following criteria at the time of their initial diagnosis:
• Cytogenetic confirmation of Philadelphia chromosome or variants of the t(9;22) translocations. Patients may have secondary chromosomal abnormalities in addition to the Philadelphia chromosome.
• Peripheral blood or bone marrow blast count \< 10%.
• Peripheral blood basophil count \< 20%.
• Platelet count ≥ 100,000 x 109/L.
• If the peripheral blood counts are unavailable from the time of their original diagnosis, but there is no evidence of accelerated- or blast-phase disease from prior clinical or other medical records, then they will be allowed to participate.
• Patients must be eighteen years of age or older.
• Patients must be actively receiving treatment for their CML with a a tyrosine kinase inhibitor, either imatinib or nilotinib.
• Patients may be receiving imatinib mesylate. Patients must be on imatinib mesylate for a minimum of 2 years, and be on a stable dose for at least one consecutive year leading up to enrollment.
• Patients may be receiving nilotinib (Tasigna) as frontline therapy or as second line therapy if the reason for the switch from imatinib to nilotinib was intolerance to imatinib. Patients cannot have been switched from imatinib to nilotinib because of a concern or demonstration for resistance to frontline imatinib. Patients must be on nilotinib for a minimum of 2 years, and be on a stable does for at least one consecutive year leading up to enrollment.
• Patients must have an ongoing complete hematologic response (CHR) on a a TKI (imatinib or nilotinib), defined as follows:
• WBC ≤ 10 x 109/L.
• Platelet count \< 450,000 x 109/L.
• No blasts or promyelocytes in peripheral blood.
• No evidence of disease-related symptoms and extramedullary disease, including the liver and spleen.

You may not qualify if:

• Patients who have had prior progression of their CML to accelerated phase or blast crisis.
• Patients who have previously undergone hematopoietic stem cell transplantation.
• Patients who have previously been treated with interferon-α.
• Patients with an absolute neutrophil count (ANC) \< 1500/mm3 and/or a platelet count \< 100,000/mm3.
• Patients with serum bilirubin, SGOT\[AST\], SGPT\[ALT\], or serum creatinine \> 1.5 x the upper limit of normal (ULN).
• Patients with an INR or PTT \> 1.5 x ULN, with the exception of patients on treatment with oral anticoagulants.
• Patients with uncontrolled medical diseases such as diabetes mellitus, neuropsychiatric disorders, infection, angina, severe hypertension, pulmonary disease (chronic obstructive pulmonary disease \[COPD\] with hypoxemia), major organ malfunction (liver, kidney) or class III or IV cardiac disease as defined by the New York Heart Association Criteria.
• Patients who are (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to Study Day 1, and (d) male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).
• Patients with a history of another active malignancy within the last five years, which required treatment with chemotherapy, hormonal therapy, or radiation therapy. Exceptions to this rule include basal cell and squamous cell skin carcinomas or cervical carcinoma in situ.
• Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.

Sponsors & Collaborators

• University of Michigan Rogel Cancer Center: lead

Study Sites (1)

Universtiy of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

peginterferon alfa-2b

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Dale L. Bixby, MD
• Organization: University of Michigan Rogel Cancer Center

dbixby@med.umich.edu

734-936-4991

Study Officials

• Dale L. Bixby, M.D.

  University of Michigan

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 13, 2007
• First Posted: December 14, 2007
• Study Start: September 1, 2007
• Primary Completion: October 1, 2010
• Study Completion: December 1, 2015
• Last Updated: January 25, 2023
• Results First Posted: January 25, 2023

Record last verified: 2023-01

Locations

US (1)